title: Expression of ribosome-binding protein 1 correlates with shorter survival in Her-2 positive breast cancer.
abstract: The aim of this study is to investigate the expression of ribosome-binding protein 1 (RRBP1) in invasive breast cancer and to analyze its relationship to clinical features and prognosis. RRBP1 expression was studied using real-time quantitative PCR and western blotting using pair-matched breast samples and immunohistochemical staining using a tissue microarray. Then the correlation between RRBP1 expression and clinicopathologic features was analyzed. RRBP1 mRNA and protein expression were significantly increased in breast cancer tissues compared with normal tissues. The protein level of RRBP1 is proved to be positively related to histological grade (P = 0.02), molecular subtype (P = 0.048) and status of Her-2 (P = 0.026) and P53 (P = 0.015). We performed a grade-stratified analysis of all patients according to the level of RRBP1 expression and found that RRBP1 overexpression highly affected overall survival in patients with early-stage (I and II) tumors (P = 0.042). Furthermore, Her-2 positive patients with negative RRBP1 expression had longer overall survival rates than those with positive RRBP1 expression (P = 0.031). Using multivariate analysis, it was determined that lymph node metastasis (LNM, P = 0.002) and RRBP1 expression (P = 0.005) were independent prognosis factors for overall survival. RRBP1 is a valuable prognostic factor in Her-2-positive breast cancer patients, indicating that RRBP1 is a potentially important target for the prediction of prognosis.
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Xiaoshuan
authors.initials: X
authors.lastname: Liang
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Shanshan
authors.initials: S
authors.lastname: Sun
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Xianyu
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Weiyang
authors.initials: W
authors.lastname: Tao
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Tong
authors.initials: T
authors.lastname: Liu
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.affiliation: Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
authors.forename: Jingshu
authors.initials: J
authors.lastname: Geng
authors.affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.|North (China) Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin, China.
authors.forename: Da
authors.initials: D
authors.lastname: Pang
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D004721:Endoplasmic Reticulum / Q000737:chemistry*; D005260:Female; D006801:Humans; D008565:Membrane Proteins / Q000032:analysis / Q000502:physiology*; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012270:Ribosomes / Q000378:metabolism*
chemical_list: D008565:Membrane Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Breast cancer; Her-2; RRBP1; histological grade; prognosis
references.citation: Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
references.citation: Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
references.citation: Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
references.citation: Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19: 6115-21.
references.citation: Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-46.
references.citation: Alaoui-Jamali MA, Paterson J, Al Moustafa AE, Yen L. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 1997; 75: 315-25.
references.citation: Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-9.
references.citation: Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC. Herceptin. Handb Exp Pharmacol 2008; 181: 183-219.
references.citation: Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-811.
references.citation: Benyamini P, Webster P, Meyer DI. Knockdown of p180 eliminates the terminal differentiation of a secretory cell line. Mol Biol Cell 2009; 20: 732-44.
references.citation: Savitz AJ, Meyer DI. Identification of a ribosome receptor in the rough endoplasmic reticulum. Nature 1990; 346: 540-4.
references.citation: Hyde M, Block-Alper L, Felix J, Webster P, Meyer DI. Induction of secretory pathway components in yeast is associated with increased stability of their mRNA. J Cell Biol 2002; 156: 993-1001.
references.citation: Cardoso CM, Groth-Pedersen L, Hoyer-Hansen M et al. Depletion of kinesin 5B affects lysosomal distribution and stability and induces peri-nuclear accumulation of autophagosomes in cancer cells. PLoS One 2009; 4: e4424.
references.citation: Krasnov GS, Oparina N, Khankin SL et al. Colorectal cancer 2D-proteomics: identification of altered protein expression. Mol Biol 2009; 43: 348-56.
references.citation: Tsai HY, Yang YF, Wu AT et al. Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. Oncogene 2013; 32: 4921-31.
references.citation: Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
references.citation: Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 2002; 118: 693-8.
references.citation: Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
references.citation: Millar EK, Graham PH, McNeil CM et al. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer 2011; 105: 272-80.
references.citation: Parker RL, Huntsman DG, Lesack DW et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002; 117: 723-8.
references.citation: Ogawa-Goto K, Tanaka K, Ueno T et al. p180 is involved in the interaction between the endoplasmic reticulum and microtubules through a novel microtubule-binding and bundling domain. Mol Biol Cell 2007; 18: 3741-51.
references.citation: Barbe L, Lundberg E, Oksvold P et al. Toward a confocal subcellular atlas of the human proteome. Mol Cell Proteomics 2008; 7: 499-508.
references.citation: Savitz AJ, Meyer DI. 180-kD ribosome receptor is essential for both ribosome binding and protein translocation. J Cell Biol 1993; 120: 853-63.
references.citation: Olsen JV, Blagoev B, Gnad F et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006; 127: 635-48.
references.citation: Wanker EE, Sun Y, Savitz AJ, Meyer DI. Functional characterization of the 180-kD ribosome receptor in vivo. J Cell Biol 1995; 130: 29-39.
references.citation: Ueno T, Tanaka K, Kaneko K et al. Enhancement of procollagen biosynthesis by p180 through augmented ribosome association on the endoplasmic reticulum in response to stimulated secretion. J Biol Chem 2010; 285: 29941-50.
references.citation: Brostrom MA, Prostko CR, Gmitter D, Brostrom CO. Independent signaling of grp78 gene transcription and phosphorylation of eukaryotic initiator factor 2 alpha by the stressed endoplasmic reticulum. J Biol Chem 1995; 270: 4127-32.
references.citation: Feng B, Yao PM, Li Y et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003; 5: 781-92.
references.citation: Gomez E, Powell ML, Bevington A, Herbert TP. A decrease in cellular energy status stimulates PERK-dependent eIF2alpha phosphorylation and regulates protein synthesis in pancreatic beta-cells. Biochem J 2008; 410: 485-93.
references.citation: Su HL, Liao CL, Lin YL. Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. J Virol 2002; 76: 4162-71.
references.citation: Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2000; 2: 326-32.
references.citation: Clarke R, Cook KL, Hu R et al. Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res 2012; 72: 1321-31.
references.citation: Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991; 27: 1372-5.
references.citation: Lemoine NR, Jain S, Silvestre F et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991; 64: 79-83.
references.citation: De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010; 36(Suppl 3): S11-5.
references.citation: Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284: 54-65.
references.citation: Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61(Suppl 2): 1-13.
references.citation: Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102-14.
references.citation: Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50: 1550-8.
references.citation: Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-60.
references.citation: Kumandan S, Mahadevan NR, Chiu K, DeLaney A, Zanetti M. Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway. Cancer Lett 2013; 329: 236-42.